Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Lipid Absorption01:24

Lipid Absorption

3.9K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disorders of childhood growth and development: precocious puberty.

FP essentials·2013
Same journal

For health, for beauty, or both? navigating trends as adolescent clinicians.

Current opinion in pediatrics·2026
Same journal

Childhood sleep disorders: practical management for the pediatrician.

Current opinion in pediatrics·2026
Same journal

Advanced therapies in management of pediatric inflammatory bowel disease.

Current opinion in pediatrics·2026
Same journal

Artificial intelligence in pediatric endoscopy for hereditary polyposis syndromes: promises and challenges.

Current opinion in pediatrics·2026
Same journal

Hormonal acne therapies in pediatrics.

Current opinion in pediatrics·2026
Same journal

Clinical implementation of artificial intelligence in adolescent mental healthcare.

Current opinion in pediatrics·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.7K

Update on pediatric hyperlipidemia.

Alia Chauhan1, Pooja Paunikar

  • 1aFamily Medicine Residency Program at North Shore-LIJ Southside Hospital, Hofstra North Shore-LIJ School of Medicine bNSLIJ Southside Hospital in Bay Shore, New York, New York, USA.

Current Opinion in Pediatrics
|February 21, 2014
PubMed
Summary
This summary is machine-generated.

National Heart Lung and Blood Institute (NHBLI) guidelines offer a balanced approach to pediatric hyperlipidemia screening and management. Early identification and intervention can improve child health outcomes and reduce healthcare costs.

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

564
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K

Related Experiment Videos

Last Updated: May 2, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.7K
High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

564
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K

Area of Science:

  • Pediatric Cardiology
  • Public Health
  • Clinical Guidelines

Background:

  • Hyperlipidemia in children is a growing concern with potential long-term cardiovascular implications.
  • National Health and Nutrition Examination Survey data indicates shifting lipid profiles in pediatric populations.
  • Concerns exist regarding the efficacy and necessity of universal screening for pediatric hyperlipidemia.

Purpose of the Study:

  • To review the National Heart Lung and Blood Institute (NHBLI) guidelines for screening and managing hyperlipidemia in children.
  • To discuss criticisms and concerns surrounding universal screening for pediatric hyperlipidemia.

Main Methods:

  • Review of NHBLI guidelines on pediatric hyperlipidemia.
  • Analysis of data from the National Health and Nutrition Examination Survey (NHANES).
  • Discussion of expert critiques on universal screening protocols.

Main Results:

  • Favorable trends observed in serum lipid levels among children (6-19 years) between 1988-1994 and 2007-2010.
  • Mean total cholesterol (TC) decreased from 165 to 160 mg/dL; elevated TC prevalence dropped from 11.3% to 8.1%.
  • However, 20% of 9-11 year olds had low HDL-C or high non-HDL-C between 2007-2010, necessitating further evaluation per NHBLI guidelines.

Conclusions:

  • NHBLI guidelines offer a balanced framework for pediatric hyperlipidemia screening and management.
  • The guidelines provide a structured approach to aid primary care physicians in treatment decisions.
  • Early identification and intervention are expected to reduce healthcare expenses and improve overall child health.